A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2019
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone; Filgrastim
- Indications Multiple myeloma
- Focus Adverse reactions
- 12 Dec 2017 Results (n=12) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 05 May 2014 New source identified and integrated (M.D. Anderson Cancer Center; 2013-0018).